FROM ME-TOO TO MECHANISM
Why the indication a drug is developed for — not just the molecule — decides its fate.
Positioning — which indication, and which patients within it — does as much as anything to decide whether a drug succeeds, yet it is still made largely by consensus and intuition. This paper sets out how that choice is made today, why good opportunities are missed, and what a rigorous, evidence-led method looks like — including, deliberately, its limits.
WHY POSITIONING IS THE DECISION THAT MAKES THE DRUG
Every drug programme rests on a decision that gets far less rigour than the molecule itself: which indication to develop it for. Choose well and a good molecule finds the patients where it wins. Choose badly and the same molecule fails an avoidable trial — or lands in a crowded “me-too” indication where it can never differentiate. Much of the money lost in pharmaceutical R&D is lost not because the molecule was bad, but because it was developed for the wrong indication.
The advantage goes not to those who screen the most molecules, but to those who position each asset into the indication where its mechanism is most likely to win — and can show their work.
WHAT THIS WHITE PAPER COVERS
- Why indication selection — not the molecule — is where pipeline value is created or destroyed, and the two kinds of positioning error that quietly strand it.
- The two ways indications get chosen today, and the trap in each: consensus that is too narrow, and unconstrained algorithmic search that is too broad.
- A mechanism-first method that pairs a biomedical knowledge graph with regulatory-grade real-world evidence — run as a self-correcting loop, not a one-way pipeline.
- What the approach deliberately cannot do — the stated limits that are part of the method, and what makes everything below them credible.
- What a deal-ready evidence package actually contains, why a patentable population is not yet a market, and what makes the method hard to copy.
INSIDE THE PAPER
- 01The decision that matters most
- 02The trend — why positioning is getting harder, and more valuable
- 03The selection trap — why indication selection so often disappoints
- 04A mechanism-first approach — start from the molecule; let the evidence decide
- 05Limits of this method — what this approach cannot do
- 06What good looks like — from hypothesis to a deal-ready evidence package
- 07The differentiator — what makes chAIron's positioning hard to copy
- 08Outlook — crowded on the obvious, empty on the non-obvious
Full sections, two figures and references come with the paper. Get your copy via the form.
WHO SHOULD READ THIS
R&D & CHIEF SCIENTIFIC OFFICERS
Pressure-test a lead-indication choice and surface defensible white space the consensus plan missed.
BUSINESS DEVELOPMENT & LICENSING
Strengthen the indication story behind an asset's value, and the case taken into a partnering room.
INVESTORS & DILIGENCE TEAMS
Judge whether a positioning rests on evidence that survives scrutiny — or on analogy and intuition.
FREQUENTLY ASKED QUESTIONS
It is an educational paper on drug positioning — the decision about which indication, and which patients within it, a drug is developed for. It argues that this choice does as much as anything to decide a programme's fate, examines how it is made today and where it goes wrong, and sets out a rigorous, mechanism-first method for making it — together with the method's stated limits.
R&D and scientific leadership, business-development and licensing teams, clinical development, and investors or diligence teams. It assumes familiarity with drug development but is written to be read by a development committee, not only by specialists.
No. The paper describes principles and their limits, not the recipe. The specific scoring methods, datasets and engineering that implement the approach are chAIron's proprietary platform and are deliberately out of scope. It contains no client-confidential information.
Complete the short form on this page. We will email the full PDF to the address you provide. There is no charge, and we will only use your details to send the paper and occasional related chAIron resources.
No. The paper is provided for general educational and informational purposes only. It is not legal, regulatory, medical, financial, investment or tax advice. Patentability, freedom-to-operate, regulatory pathway and commercial decisions require qualified professional advisers.
RELATED
FROM ME-TOO TO MECHANISM — FOR YOUR ASSET
Read the paper, then talk to us about positioning a specific molecule — peer to peer.
BOOK AN INDICATION-STRATEGY CALL© 2026 chAIron SA. Educational; not legal, regulatory, financial or investment advice.